Leerink Partners analyst Michael Cherny raised the price target on Quest Diagnostics (NYSE: DGX) to $210.00 (from $203.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE